SGLT2抑制剂、GLP-1受体激动剂及联合治疗预防2型糖尿病肾衰竭的目标试验模拟研究
该目标试验模拟研究利用Optum Labs电子健康记录数据,纳入2015年至2024年间新使用SGLT2抑制剂、GLP-1受体激动剂或联合治疗的2型糖尿病成人,比较肾衰竭风险。结果显示,与GLP-1受体激动剂相比,SGLT2抑制剂与较低的肾衰竭风险相关(HR 0.82;95%CI 0.73-0.91),联合治疗在合并CKD或心衰的高危患者中风险更低(HR 0.54;95%CI 0.30-0.97)。
要点
- SGLT2抑制剂较GLP-1受体激动剂显著降低肾衰竭风险。
- 联合治疗在合并CKD或心衰患者中肾衰竭风险更低。
- 临床应优先考虑SGLT2抑制剂以预防肾衰竭进展。
核心结论
- 在2型糖尿病患者中,与GLP-1受体激动剂相比,SGLT2抑制剂与较低的肾衰竭风险相关。
- 在合并CKD或心衰的高危患者中,联合治疗可能进一步降低肾衰竭风险。
研究设计与样本
- 采用目标试验模拟研究,新使用者、活性对照设计,数据来自Optum Labs Data Warehouse的去标识电子健康记录。
- 纳入2015年1月1日至2024年6月29日期间被处方GLP-1受体激动剂、SGLT2抑制剂或两者的2型糖尿病成人。
- 共504,151人,中位随访2.35年(四分位距1.09-4.32),发生2965例肾衰竭事件。
- 使用逆概率治疗加权Cox比例风险回归模型,分别进行意向性治疗和实际治疗分析。
主要发现
- 意向性治疗分析中,与GLP-1受体激动剂相比,SGLT2抑制剂肾衰竭风险显著更低(HR 0.82;95%CI 0.73-0.91),联合治疗无显著差异(HR 0.72;95%CI 0.45-1.15)。
- 实际治疗模型结果与意向性治疗分析相似。
- 在合并CKD或心衰的患者中,与GLP-1受体激动剂相比,联合治疗肾衰竭风险显著更低(HR 0.54;95%CI 0.30-0.97)。
- 平均处方时长:GLP-1受体激动剂0.69年,SGLT2抑制剂0.62年,联合治疗0.44年。
临床怎么用
- 对于2型糖尿病患者,为预防肾衰竭进展,应优先使用SGLT2抑制剂。
- 对于合并CKD或心衰的高危2型糖尿病患者,可考虑SGLT2抑制剂与GLP-1受体激动剂联合治疗以进一步降低肾衰竭风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Compared with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with a lower risk of kidney failure among individuals with type 2 diabetes. Use of combination SGLT2 inhibitor and glucagon-like peptide-1 receptor agonist was infrequent but associated with lower kidney failure risk in high-risk individuals. Providers should prioritize SGLT2 inhibitors in patients with type 2 diabetes to prevent progression to kidney failure. BACKGROUND: The relative effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for kidney protection, both individually and in combination, is incompletely understood. We sought to compare associations of GLP-1 receptor agonists, SGLT2 inhibitors, and both medications in combination with incident kidney failure among individuals with type 2 diabetes. METHODS: We conducted a target trial emulation study with new user, active comparator design using deidentified electronic health records data from Optum Labs Data Warehouse. We included adults with type 2 diabetes who were prescribed a GLP-1 receptor agonist, SGLT2 inhibitor, or both between January 1, 2015, and June 29, 2024. We estimated the association of medication class with incident kidney failure using inverse probability of treatment weighted Cox proportional hazards regression models in both intention-to-treat and as-treated methodologies. RESULTS: There were 504,151 individuals with 2965 kidney failure events during a median 2.35 (interquartile range 1.09-4.32) years of follow-up. Average prescription duration was 0.69 years for GLP-1 receptor agonists, 0.62 years for SGLT2 inhibitors, and 0.44 years for combination therapy. In the intention-to-treat analysis, compared with GLP-1 receptor agonists, the risk of kidney failure was significantly lower with SGLT2 inhibitors (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.73 to 0.91) but no different with combination therapy (HR, 0.72; 95% CI, 0.45 to 1.15). The results were similar in the as-treated model. Among individuals with CKD or heart failure, the risk of kidney failure was significantly lower with combination therapy compared with GLP-1 receptor agonists (HR, 0.54; 95% CI, 0.30 to 0.97). CONCLUSIONS: SGLT2 inhibitors were associated with a lower risk of kidney failure compared to GLP-1 receptor agonists. Among high-risk patients with type 2 diabetes and CKD or heart failure, combination therapy may further reduce the risk of kidney failure.
引用
- Blum MF, Mehta S, Surapaneni A, et al. A Target Trial Emulation Study of SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Combination Therapy in Preventing Kidney Failure in Type 2 Diabetes. Clin J Am Soc Nephrol. 2025. PMID: 41400456. doi:10.2215/CJN.0000000902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。